Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. SY08-02 - SY08-02
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 05/2019, Volume 25, Issue 10, pp. 3096 - 3103
Purpose: The natural history and prognosis of appendiceal adenocarcinomas differ from those of adenocarcinomas arising in other large bowel sites. We aimed to...
PAPILLARY MUCINOUS NEOPLASMS | FREQUENT GNAS MUTATIONS | ONCOLOGY | PREDICTIVE BIOMARKERS | ADENOMA | PSEUDOMYXOMA PERITONEI | LOW-GRADE | CARCINOMATOSIS | GENERATION | INHIBITOR | CHEMOTHERAPY
PAPILLARY MUCINOUS NEOPLASMS | FREQUENT GNAS MUTATIONS | ONCOLOGY | PREDICTIVE BIOMARKERS | ADENOMA | PSEUDOMYXOMA PERITONEI | LOW-GRADE | CARCINOMATOSIS | GENERATION | INHIBITOR | CHEMOTHERAPY
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e16236 - e16236
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2018, Volume 20, Issue suppl_6, pp. vi237 - vi237
Abstract BACKGROUND Gliosarcoma (GS) accounts for approximately 2% of WHO grade 4 gliomas and have a worse prognosis relative to glioblastoma (GBM)....
Abstracts
Abstracts
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2018, Volume 20, Issue suppl_6, pp. vi240 - vi241
Abstract BACKGROUND PD-1 and PD-L1 expression has not been well-described in PCNSL. In one report of 20 PCNSL tumors, PD-1 and PD-L1 expression on tumor cells...
Abstracts
Abstracts
Journal Article
Cancer Research, ISSN 0008-5472, 05/2003, Volume 63, Issue 9, pp. 2088 - 2095
Recombinant adenoviruses are presently being tested clinically as a new strategy for the treatment of cancer. An important determining factor for the...
KINASE PATHWAY | REPLICATION | TRANSGENE EXPRESSION | EPITHELIAL-CELLS | ONCOLOGY | MAP KINASE | GENE-THERAPY | TUMOR-CELLS | E-CADHERIN | TIGHT JUNCTION | CARCINOMA | Green Fluorescent Proteins | Up-Regulation | Colorectal Neoplasms - virology | MAP Kinase Signaling System - physiology | Phosphorylation | Pancreatic Neoplasms - metabolism | Receptors, Virus - biosynthesis | Colorectal Neoplasms - genetics | Humans | Transcriptional Activation | Gene Expression Regulation, Neoplastic | Coxsackie and Adenovirus Receptor-Like Membrane Protein | Receptors, Virus - genetics | Luminescent Proteins - biosynthesis | Proto-Oncogene Proteins c-raf - physiology | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Membrane - metabolism | Tumor Cells, Cultured | Colorectal Neoplasms - metabolism | Protein-Serine-Threonine Kinases - metabolism | Pancreatic Neoplasms - virology | Proto-Oncogene Proteins c-raf - biosynthesis | Recombinant Fusion Proteins - biosynthesis | Colorectal Neoplasms - enzymology | Proto-Oncogene Proteins c-raf - genetics | Protein-Serine-Threonine Kinases - physiology | Enzyme Inhibitors - pharmacology | Pancreatic Neoplasms - enzymology | Adenoviruses, Human - physiology | Pancreatic Neoplasms - genetics | G1 Phase - physiology | Proto-Oncogene Proteins c-raf - metabolism | Animals | MAP Kinase Signaling System - drug effects | Mitogen-Activated Protein Kinases - antagonists & inhibitors | Mitogen-Activated Protein Kinases - physiology | Dogs | Recombinant Fusion Proteins - genetics | Luminescent Proteins - genetics | Mice | Proto-Oncogene Proteins c-raf - antagonists & inhibitors | Adenoviruses, Human - metabolism | MAP Kinase Kinase Kinase 1 | Mitogen-Activated Protein Kinases - metabolism
KINASE PATHWAY | REPLICATION | TRANSGENE EXPRESSION | EPITHELIAL-CELLS | ONCOLOGY | MAP KINASE | GENE-THERAPY | TUMOR-CELLS | E-CADHERIN | TIGHT JUNCTION | CARCINOMA | Green Fluorescent Proteins | Up-Regulation | Colorectal Neoplasms - virology | MAP Kinase Signaling System - physiology | Phosphorylation | Pancreatic Neoplasms - metabolism | Receptors, Virus - biosynthesis | Colorectal Neoplasms - genetics | Humans | Transcriptional Activation | Gene Expression Regulation, Neoplastic | Coxsackie and Adenovirus Receptor-Like Membrane Protein | Receptors, Virus - genetics | Luminescent Proteins - biosynthesis | Proto-Oncogene Proteins c-raf - physiology | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Membrane - metabolism | Tumor Cells, Cultured | Colorectal Neoplasms - metabolism | Protein-Serine-Threonine Kinases - metabolism | Pancreatic Neoplasms - virology | Proto-Oncogene Proteins c-raf - biosynthesis | Recombinant Fusion Proteins - biosynthesis | Colorectal Neoplasms - enzymology | Proto-Oncogene Proteins c-raf - genetics | Protein-Serine-Threonine Kinases - physiology | Enzyme Inhibitors - pharmacology | Pancreatic Neoplasms - enzymology | Adenoviruses, Human - physiology | Pancreatic Neoplasms - genetics | G1 Phase - physiology | Proto-Oncogene Proteins c-raf - metabolism | Animals | MAP Kinase Signaling System - drug effects | Mitogen-Activated Protein Kinases - antagonists & inhibitors | Mitogen-Activated Protein Kinases - physiology | Dogs | Recombinant Fusion Proteins - genetics | Luminescent Proteins - genetics | Mice | Proto-Oncogene Proteins c-raf - antagonists & inhibitors | Adenoviruses, Human - metabolism | MAP Kinase Kinase Kinase 1 | Mitogen-Activated Protein Kinases - metabolism
Journal Article
Nature Medicine, ISSN 1078-8956, 2000, Volume 6, Issue 10, pp. 1128 - 1133
The adenovirus mutant dl1520 (ONYX-015) does not express the E1B-55K protein that binds and inactivates p53. This virus replicates in tumor cells with mutant...
MEDICINE, RESEARCH & EXPERIMENTAL | SUPPRESSOR | P19(ARF) | P53 STATUS | BIOCHEMISTRY & MOLECULAR BIOLOGY | DNA-DAMAGE | CELL BIOLOGY | G ARREST | MDM2 | INFECTION | ACCUMULATION | PROTEINS | EXPRESSION
MEDICINE, RESEARCH & EXPERIMENTAL | SUPPRESSOR | P19(ARF) | P53 STATUS | BIOCHEMISTRY & MOLECULAR BIOLOGY | DNA-DAMAGE | CELL BIOLOGY | G ARREST | MDM2 | INFECTION | ACCUMULATION | PROTEINS | EXPRESSION
Journal Article
Cancer Research, ISSN 0008-5472, 04/2010, Volume 70, Issue 8 Supplement, pp. SY25-03 - SY25-03
Journal Article
Cancer Research, ISSN 0008-5472, 01/2009, Volume 69, Issue 2, pp. 565 - 572
Specific inhibitors of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK) have been developed that efficiently inhibit...
STEM-CELLS | PTEN LOSS | PIK3CA MUTATIONS | GENE | ONCOLOGY | PI3K PATHWAY | OVARIAN | EXPRESSION | CARCINOMA | ESTROGEN-RECEPTOR | LINES | Cyclin D1 - metabolism | Humans | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Phosphatidylinositol 3-Kinases - metabolism | G1 Phase - drug effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Breast Neoplasms - drug therapy | Drug Synergism | Mitogen-Activated Protein Kinase Kinases - metabolism | Breast Neoplasms - enzymology | Cyclin D1 - antagonists & inhibitors | Feedback, Physiological | Receptor, Epidermal Growth Factor - metabolism | MAP Kinase Signaling System - drug effects | Breast Neoplasms - pathology | Cell Line, Tumor | Protein Kinase Inhibitors - pharmacology | Camptothecin - pharmacology | Index Medicus
STEM-CELLS | PTEN LOSS | PIK3CA MUTATIONS | GENE | ONCOLOGY | PI3K PATHWAY | OVARIAN | EXPRESSION | CARCINOMA | ESTROGEN-RECEPTOR | LINES | Cyclin D1 - metabolism | Humans | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Phosphatidylinositol 3-Kinases - metabolism | G1 Phase - drug effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Breast Neoplasms - drug therapy | Drug Synergism | Mitogen-Activated Protein Kinase Kinases - metabolism | Breast Neoplasms - enzymology | Cyclin D1 - antagonists & inhibitors | Feedback, Physiological | Receptor, Epidermal Growth Factor - metabolism | MAP Kinase Signaling System - drug effects | Breast Neoplasms - pathology | Cell Line, Tumor | Protein Kinase Inhibitors - pharmacology | Camptothecin - pharmacology | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 2017, Volume 77, Issue 7, pp. 1575 - 1585
Molecular networks governing responses to targeted therapies in cancer cells are complex dynamic systems that demonstrate nonintuitive behaviors. We applied a...
BREAST-CANCER | KAPPA-B ACTIVATION | SIGNALING PATHWAYS | PROTEIN | MEK INHIBITION | ONCOLOGY | KINASE | GENE-EXPRESSION | PROLIFERATION | TRIBBLES | Promoter Regions, Genetic | Cell Survival | Protein-Serine-Threonine Kinases - physiology | Humans | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Protein-Serine-Threonine Kinases - genetics | Proto-Oncogene Proteins c-akt - physiology | Breast Neoplasms - drug therapy | Breast Neoplasms - genetics | Cell Cycle | Cyclin D1 - genetics | Breast Neoplasms - pathology | Bayes Theorem | NF-kappa B - physiology | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Line, Tumor | Phosphatidylinositol 3-Kinases - physiology | Female | Signal Transduction - physiology | Intracellular Signaling Peptides and Proteins - physiology | Intracellular Signaling Peptides and Proteins - genetics | Cell culture | Regulators | Transcription factors | Copy number | Genes | Cyclin D1 | Machinery | Signal transduction | Interrogation | Cell cycle | Mathematical models | Inhibition | Interleukin 8 | Multidimensional data | Cell survival | Computer simulation | Breast cancer | Gene expression | Survival | Signaling | Computer applications | Predictions | Transduction | Bayesian analysis | Cancer | Apoptosis | apoptosis | MEK | Molecular network biology | NFκB | cell cycle regulation | TRIB1
BREAST-CANCER | KAPPA-B ACTIVATION | SIGNALING PATHWAYS | PROTEIN | MEK INHIBITION | ONCOLOGY | KINASE | GENE-EXPRESSION | PROLIFERATION | TRIBBLES | Promoter Regions, Genetic | Cell Survival | Protein-Serine-Threonine Kinases - physiology | Humans | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Protein-Serine-Threonine Kinases - genetics | Proto-Oncogene Proteins c-akt - physiology | Breast Neoplasms - drug therapy | Breast Neoplasms - genetics | Cell Cycle | Cyclin D1 - genetics | Breast Neoplasms - pathology | Bayes Theorem | NF-kappa B - physiology | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Line, Tumor | Phosphatidylinositol 3-Kinases - physiology | Female | Signal Transduction - physiology | Intracellular Signaling Peptides and Proteins - physiology | Intracellular Signaling Peptides and Proteins - genetics | Cell culture | Regulators | Transcription factors | Copy number | Genes | Cyclin D1 | Machinery | Signal transduction | Interrogation | Cell cycle | Mathematical models | Inhibition | Interleukin 8 | Multidimensional data | Cell survival | Computer simulation | Breast cancer | Gene expression | Survival | Signaling | Computer applications | Predictions | Transduction | Bayesian analysis | Cancer | Apoptosis | apoptosis | MEK | Molecular network biology | NFκB | cell cycle regulation | TRIB1
Journal Article
Journal of Molecular Medicine, ISSN 0946-2716, 9/2011, Volume 89, Issue 9, pp. 877 - 889
Targeting of pathways downstream of RAS represents a promising therapeutic strategy for pancreatic cancer, the fourth leading cause of cancer-related death in...
Human Genetics | EGFR pathway | Biomedicine | Cancer signal transduction | PI3K | Chloroquine | mTOR | Pancreatic adenocarcinoma | Internal Medicine | Molecular Medicine | Autophagy | Apoptosis | MAMMALIAN TARGET | TRANSCRIPTION FACTORS | RAPAMYCIN | MEDICINE, RESEARCH & EXPERIMENTAL | SIGNALING PATHWAYS | ACTIVATION | PHOSPHORYLATION | INDUCTION | BREAST-CANCER CELLS | GENETICS & HEREDITY | NF-KAPPA-B | EXPRESSION | Pancreatic Neoplasms - metabolism | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Humans | Apoptosis - genetics | Antineoplastic Agents - therapeutic use | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Autophagy - drug effects | Pancreatic Neoplasms - drug therapy | TOR Serine-Threonine Kinases - antagonists & inhibitors | Adenocarcinoma - metabolism | Cell Death - genetics | Female | Adenocarcinoma - genetics | Autophagy - genetics | Cell Death - drug effects | Pancreatic Neoplasms - genetics | Signal Transduction - genetics | Adenocarcinoma - drug therapy | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | Mice, Nude | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Autophagy (Cytology) | Care and treatment | Enzyme inhibitors | Pancreatic cancer | Cellular signal transduction | Research | Health aspects
Human Genetics | EGFR pathway | Biomedicine | Cancer signal transduction | PI3K | Chloroquine | mTOR | Pancreatic adenocarcinoma | Internal Medicine | Molecular Medicine | Autophagy | Apoptosis | MAMMALIAN TARGET | TRANSCRIPTION FACTORS | RAPAMYCIN | MEDICINE, RESEARCH & EXPERIMENTAL | SIGNALING PATHWAYS | ACTIVATION | PHOSPHORYLATION | INDUCTION | BREAST-CANCER CELLS | GENETICS & HEREDITY | NF-KAPPA-B | EXPRESSION | Pancreatic Neoplasms - metabolism | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Humans | Apoptosis - genetics | Antineoplastic Agents - therapeutic use | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Autophagy - drug effects | Pancreatic Neoplasms - drug therapy | TOR Serine-Threonine Kinases - antagonists & inhibitors | Adenocarcinoma - metabolism | Cell Death - genetics | Female | Adenocarcinoma - genetics | Autophagy - genetics | Cell Death - drug effects | Pancreatic Neoplasms - genetics | Signal Transduction - genetics | Adenocarcinoma - drug therapy | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | Mice, Nude | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Autophagy (Cytology) | Care and treatment | Enzyme inhibitors | Pancreatic cancer | Cellular signal transduction | Research | Health aspects
Journal Article
Cancer Discovery, ISSN 2159-8274, 02/2018, Volume 8, Issue 2, pp. 164 - 173
"Liquid biopsy" approaches analyzing cell-free DNA (cfDNA) from the blood of patients with cancer are increasingly utilized in clinical practice. However, it...
TARGETED THERAPY | KRAS MUTATIONS | HETEROGENEITY | EGFR MONOCLONAL-ANTIBODIES | EVOLUTION | ONCOLOGY | CLONAL HEMATOPOIESIS | ACQUIRED-RESISTANCE | EXTRACELLULAR DOMAIN | BLOCKADE | CETUXIMAB RESISTANCE | Cell-free DNA | colorectal cancer | circulating tumor DNA
TARGETED THERAPY | KRAS MUTATIONS | HETEROGENEITY | EGFR MONOCLONAL-ANTIBODIES | EVOLUTION | ONCOLOGY | CLONAL HEMATOPOIESIS | ACQUIRED-RESISTANCE | EXTRACELLULAR DOMAIN | BLOCKADE | CETUXIMAB RESISTANCE | Cell-free DNA | colorectal cancer | circulating tumor DNA
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 02/2015, Volume 13, Issue 2, pp. 194 - 227
Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Adenocarcinoma is more common in North America and Western European countries,...
PHASE-II TRIAL | POSITRON-EMISSION-TOMOGRAPHY | COMBINED-MODALITY THERAPY | GASTROESOPHAGEAL JUNCTION | ONCOLOGY | DOCETAXEL PLUS CISPLATIN | GASTRIC-CANCER | SQUAMOUS-CELL CARCINOMA | RANDOMIZED-TRIAL | PREOPERATIVE CHEMORADIOTHERAPY | METASTATIC ADENOCARCINOMA | Esophagogastric Junction - pathology | Esophageal Neoplasms - diagnosis | Stomach Neoplasms - diagnosis | Esophageal Neoplasms - therapy | Humans | Stomach Neoplasms - therapy
PHASE-II TRIAL | POSITRON-EMISSION-TOMOGRAPHY | COMBINED-MODALITY THERAPY | GASTROESOPHAGEAL JUNCTION | ONCOLOGY | DOCETAXEL PLUS CISPLATIN | GASTRIC-CANCER | SQUAMOUS-CELL CARCINOMA | RANDOMIZED-TRIAL | PREOPERATIVE CHEMORADIOTHERAPY | METASTATIC ADENOCARCINOMA | Esophagogastric Junction - pathology | Esophageal Neoplasms - diagnosis | Stomach Neoplasms - diagnosis | Esophageal Neoplasms - therapy | Humans | Stomach Neoplasms - therapy
Journal Article
Neuro-Oncology, ISSN 1522-8517, 05/2017, Volume 19, Issue 5, pp. 699 - 709
Molecular profiling is revolutionizing cancer diagnostics and leading to personalized therapeutic approaches. Herein we describe our clinical experience...
Targeted therapeutics | Next-generation sequencing | Personalized therapy | Pediatric brain tumors | Molecular profling | MISMATCH-REPAIR DEFICIENCY | ASTROCYTOMA | MAP2K1 | next-generation sequencing | LANDSCAPE | pediatric brain tumors | CANCER | SOMATIC MUTATIONS | CLINICAL NEUROLOGY | BRAIN-TUMORS | ONCOLOGY | targeted therapeutics | molecular profiling | personalized therapy | FGFR1 | Prognosis | Brain Neoplasms - diagnosis | Humans | Brain Neoplasms - genetics | Child, Preschool | Infant | Male | Antineoplastic Agents - therapeutic use | Brain Neoplasms - drug therapy | Molecular Targeted Therapy | Young Adult | Brain Neoplasms - classification | Adolescent | Germ-Line Mutation | Adult | Female | Biomarkers, Tumor - genetics | High-Throughput Nucleotide Sequencing - methods | Child | Pediatric Neuro-Oncology
Targeted therapeutics | Next-generation sequencing | Personalized therapy | Pediatric brain tumors | Molecular profling | MISMATCH-REPAIR DEFICIENCY | ASTROCYTOMA | MAP2K1 | next-generation sequencing | LANDSCAPE | pediatric brain tumors | CANCER | SOMATIC MUTATIONS | CLINICAL NEUROLOGY | BRAIN-TUMORS | ONCOLOGY | targeted therapeutics | molecular profiling | personalized therapy | FGFR1 | Prognosis | Brain Neoplasms - diagnosis | Humans | Brain Neoplasms - genetics | Child, Preschool | Infant | Male | Antineoplastic Agents - therapeutic use | Brain Neoplasms - drug therapy | Molecular Targeted Therapy | Young Adult | Brain Neoplasms - classification | Adolescent | Germ-Line Mutation | Adult | Female | Biomarkers, Tumor - genetics | High-Throughput Nucleotide Sequencing - methods | Child | Pediatric Neuro-Oncology
Journal Article
Molecular Cancer Research, ISSN 1541-7786, 05/2018, Volume 16, Issue 5, pp. 805 - 812
The efficacy of immunotherapy varies widely among different gastrointestinal cancers. Response to immune checkpoint inhibitors is shown to correlate with tumor...
Gastrointestinal Neoplasms - genetics | Colorectal Neoplasms - genetics | Humans | Brain Neoplasms - genetics | Male | Neoplastic Syndromes, Hereditary - metabolism | B7-H1 Antigen - genetics | Brain Neoplasms - metabolism | Gastrointestinal Neoplasms - pathology | B7-H1 Antigen - biosynthesis | Neoplastic Syndromes, Hereditary - genetics | Mutation | Colorectal Neoplasms - metabolism | Cohort Studies | Gastrointestinal Neoplasms - metabolism | Clinical trials | Microsatellite instability | Paraffin | Gene sequencing | Missense mutation | Intestine | Immunotherapy | Mismatch repair | Colon | Pancreas | Repair | Movement disorders | Deoxyribonucleic acid--DNA | Medical research | Microsatellites | Stability | Stability analysis | Gene expression | Immune checkpoint | Cell death | PD-L1 protein | DNA sequencing | Cancer | Neuroendocrine tumors | Tumors | Apoptosis
Gastrointestinal Neoplasms - genetics | Colorectal Neoplasms - genetics | Humans | Brain Neoplasms - genetics | Male | Neoplastic Syndromes, Hereditary - metabolism | B7-H1 Antigen - genetics | Brain Neoplasms - metabolism | Gastrointestinal Neoplasms - pathology | B7-H1 Antigen - biosynthesis | Neoplastic Syndromes, Hereditary - genetics | Mutation | Colorectal Neoplasms - metabolism | Cohort Studies | Gastrointestinal Neoplasms - metabolism | Clinical trials | Microsatellite instability | Paraffin | Gene sequencing | Missense mutation | Intestine | Immunotherapy | Mismatch repair | Colon | Pancreas | Repair | Movement disorders | Deoxyribonucleic acid--DNA | Medical research | Microsatellites | Stability | Stability analysis | Gene expression | Immune checkpoint | Cell death | PD-L1 protein | DNA sequencing | Cancer | Neuroendocrine tumors | Tumors | Apoptosis
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 01/2017, Volume 15, Issue 1, pp. 3 - 8
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. 3076 - 3076
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2016, Volume 22, Issue 1, pp. 61 - 68
Purpose: On the basis of preclinical evidence of synergistic activity between MEK and EGFR inhibitors in pancreatic ductal adenocarcinoma (PDAC), we evaluated...
PATHWAYS | ONCOLOGY | TRAMETINIB | E-CADHERIN EXPRESSION | KINASE | GROWTH | RECEPTOR | CANCER | GEMCITABINE | ERLOTINIB | FEEDBACK | Adenocarcinoma - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Molecular Targeted Therapy | Pancreatic Neoplasms - drug therapy | Benzimidazoles - administration & dosage | DNA, Neoplasm - blood | Aged, 80 and over | Adult | Female | Pancreatic Neoplasms - mortality | Pancreatic Neoplasms - pathology | Erlotinib Hydrochloride - administration & dosage | Kaplan-Meier Estimate | Adenocarcinoma - drug therapy | Retreatment | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplastic Cells, Circulating | Biomarkers | Aged | Neoplasm Staging | Adenocarcinoma - mortality | clinical trial | pancreatic cancer | MEK | EGFR | molecular subtype
PATHWAYS | ONCOLOGY | TRAMETINIB | E-CADHERIN EXPRESSION | KINASE | GROWTH | RECEPTOR | CANCER | GEMCITABINE | ERLOTINIB | FEEDBACK | Adenocarcinoma - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Molecular Targeted Therapy | Pancreatic Neoplasms - drug therapy | Benzimidazoles - administration & dosage | DNA, Neoplasm - blood | Aged, 80 and over | Adult | Female | Pancreatic Neoplasms - mortality | Pancreatic Neoplasms - pathology | Erlotinib Hydrochloride - administration & dosage | Kaplan-Meier Estimate | Adenocarcinoma - drug therapy | Retreatment | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplastic Cells, Circulating | Biomarkers | Aged | Neoplasm Staging | Adenocarcinoma - mortality | clinical trial | pancreatic cancer | MEK | EGFR | molecular subtype
Journal Article
Physical Biology, ISSN 1478-3967, 02/2012, Volume 9, Issue 1, pp. 016003 - 016003
Hematologic spread of carcinoma results in incurable metastasis; yet, the basic characteristics and travel mechanisms of cancer cells in the bloodstream are...
SURVIVAL | CIRCULATING-TUMOR-CELLS | BIOPHYSICS | BIOCHEMISTRY & MOLECULAR BIOLOGY | Biopsy - methods | Prostatic Neoplasms - pathology | Neoplastic Cells, Circulating - pathology | Humans | Middle Aged | Pancreatic Neoplasms - pathology | Image Interpretation, Computer-Assisted | Male | Young Adult | Keratins - metabolism | Breast Neoplasms - pathology | Sensitivity and Specificity | Adult | Female | breast cancer | pancreatic cancer | prostate cancer | circulating tumor cells | fluid biopsy | microtumor emboli
SURVIVAL | CIRCULATING-TUMOR-CELLS | BIOPHYSICS | BIOCHEMISTRY & MOLECULAR BIOLOGY | Biopsy - methods | Prostatic Neoplasms - pathology | Neoplastic Cells, Circulating - pathology | Humans | Middle Aged | Pancreatic Neoplasms - pathology | Image Interpretation, Computer-Assisted | Male | Young Adult | Keratins - metabolism | Breast Neoplasms - pathology | Sensitivity and Specificity | Adult | Female | breast cancer | pancreatic cancer | prostate cancer | circulating tumor cells | fluid biopsy | microtumor emboli
Journal Article